Global Blood Therapeutics, Inc.
GBT evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Lead Asset:
- gbt601 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for GBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
gbt601 (Phase 1)
Next Catalyst
—
Tracking 3 pipeline candidates · 2 FDA decisions for Global Blood Therapeutics, Inc..
Run Global Blood Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Global Blood Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Global Blood Therapeutics, Inc.'s lead drug candidate?
Global Blood Therapeutics, Inc.'s most advanced tracked candidate is gbt601 (Phase 1) for Sickle cell disease (SCD).
Who is the CEO of Global Blood Therapeutics, Inc.?
South San Francisco is the chief executive officer of Global Blood Therapeutics, Inc. (GBT).
What therapeutic areas does Global Blood Therapeutics, Inc. focus on?
Global Blood Therapeutics, Inc. develops therapies across Rare Disease, Cardiovascular, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.